Vaccine Stocks' Wild Ride Continues As FDA Reportedly Mulls Booster Shots


Investor's Business Daily 12 August, 2021 - 03:06pm 49 views

Vaccine stocks Moderna (MRNA) and BioNTech (BNTX) rose Thursday on a report the Food and Drug Administration will soon authorize a third Covid shot for immunocompromised people.

The update to the original emergency use authorizations that allowed Covid vaccines to be used could come as soon as Thursday, according to NBC News, which cited two people familiar with the plan. Last month, a panel of advisors to the Centers for Disease Control and Prevention urged booster shots for immunocompromised adults.

On the stock market today, BioNTech stock jumped 4.1% to 374.02. Moderna stock climbed 1.6% to 391.42. Fellow vaccine stock and BioNTech partner Pfizer (PFE) popped 2% to 47.24.

All three vaccine stocks have boomeranged this week. BioNTech, Moderna and Pfizer stocks roared to record highs on Tuesday, only to take a collective tumble on Wednesday. But the possibility of FDA-authorized booster shots sent them higher again on Thursday.

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

No Covid vaccine is 100% effective against infection. And people with compromised immune systems are more susceptible even after being inoculated. That's because their immune systems might not have effectively responded to the shots.

It's unclear which people would be eligible for a third booster shot. The CDC estimates roughly 2.7% of U.S. adults are immunocompromised. This group includes cancer patients, organ transplant recipients, people living with HIV and others.

Immunocompromised people are more likely to have a severe and prolonged case of Covid, transmit the virus to other people in their house and experience a breakthrough infection following vaccination. Of people in U.S. hospitals with breakthrough cases, 44% are immunocompromised.

Adding a third booster shot could help already strong sales for the three vaccine stocks.

In the second quarter, Pfizer guided to $33.5 billion in full-year sales of its BioNTech-partnered Covid shot. That's based on signed contracts for 2.1 billion doses to be delivered this year. Both numbers are likely to increase as Pfizer and BioNTech ink new deals.

Moderna said it had signed deals for $20 billion worth of Covid vaccine doses in 2021. This year, the company says it can manufacture 800 million to 1 billion doses. For 2022, Moderna already has signed deals for $12 billion worth of product and options for 8 $billion more.

5:11 AM ET Is AbbVie stock a buy or a sell as it works on a next-generation version of Biogen's Alzheimer's disease treatment,...

5:11 AM ET Is AbbVie stock a buy or a sell as it...

Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!

Get market updates, educational videos, webinars, and stock analysis.

Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.

Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.

*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.

Ownership data provided by Refinitiv and Estimates data provided by FactSet.

© 2000-2021 Investor's Business Daily, LLC. All rights reserved

Read full article at Investor's Business Daily

Business Stories